Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
David Nierengarten

David Nierengarten Analyst Performance

Managing Director, Equity Research at Wedbush

David Nierengarten is a stock analyst at Wedbush focused in the healthcare sector, covering 40 publicly traded companies. Over the past year, David Nierengarten has issued 93 stock ratings, including buy and hold recommendations. While full access to David Nierengarten's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Nierengarten's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
141 Last 11 Years
Buy Recommendations
77.70% 108 Buy Ratings
Companies Covered
40 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy77.7%108 ratings
Hold22.3%31 ratings
Sell0.0%0 ratings

Out of 139 total stock ratings issued by David Nierengarten at Wedbush, the majority (77.7%) have been Buy recommendations, followed by 22.3% Hold.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
95.0% of companies on NASDAQ
38 companies
NYSE
2.5% of companies on NYSE
1 company
NYSEAMERICAN
2.5% of companies on NYSEAMERICAN
1 company

David Nierengarten, an analyst at Wedbush, currently covers 40 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
39 companies		97.5%
Finance
1 company		2.5%

David Nierengarten of Wedbush specializes in stock coverage within the Healthcare sector, with additional focus on Finance companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
34 companies		85.0%
PHARMACEUTICALS
4 companies		10.0%
HEALTHCARE EQUIPMENT & SUPPLIES
1 company		2.5%
FINANCIAL SERVICES
1 company		2.5%

About David Nierengarten

David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models. In addition, David has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor. David received his B.S. in Biochemistry from the University of Wisconsin-Madison, and Ph.D. in Molecular and Cell Biology from the University of California at Berkeley.

David Nierengarten's Ratings History at Wedbush

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
7/30/2026Boost Price Target$28.99$40.00Outperform
Xencor, Inc. stock logo
XNCR
Xencor
7/30/2026Reiterated Rating$19.86$26.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
7/29/2026Boost Price Target$79.83$99.00Outperform
argenex SE stock logo
ARGX
argenex
7/28/2026Boost Price Target$888.82$1,050.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
7/24/2026Boost Price Target$19.99$20.00Neutral
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
7/23/2026Reiterated Rating$6.51$11.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
7/21/2026Reiterated Rating$22.22$31.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
7/21/2026Reiterated Rating$50.78$58.00Outperform
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
7/13/2026Reiterated Rating$38.03$55.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
7/10/2026Boost Price Target$15.44$17.00Neutral
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
7/6/2026Reiterated Rating$11.87$22.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6/30/2026Boost Price Target$96.15$110.00Neutral
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
6/29/2026Boost Price Target$59.96$72.00Outperform
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
6/23/2026Reiterated Rating$0.87$5.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
6/22/2026Downgrade$132.61$135.00Neutral
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
6/16/2026Reiterated Rating$81.95$100.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
6/15/2026Reiterated Rating$13.39$12.00Neutral
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
6/12/2026Reiterated Rating$21.51$35.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
6/12/2026Reiterated Rating$18.76$31.00Outperform
argenex SE stock logo
ARGX
argenex
6/11/2026Reiterated Rating$882.46$1,000.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
6/10/2026Reiterated Rating$69.99$88.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
6/9/2026Downgrade$122.87$124.00Neutral
argenex SE stock logo
ARGX
argenex
6/4/2026Reiterated Rating$813.14$1,000.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6/2/2026Upgrade$129.69$90.00Neutral
ODTX
Odyssey Therapeutics
6/2/2026Initiated Coverage$16.96$30.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
5/29/2026Reiterated Rating$35.21$55.00Outperform
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
5/28/2026Initiated Coverage$25.21$35.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
5/28/2026Reiterated Rating$107.38$125.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
5/27/2026Boost Price Target$84.60$135.00Outperform
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
5/26/2026Initiated Coverage$25.89$42.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
5/12/2026Reiterated Rating$14.42$12.00Neutral
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
5/8/2026Boost Price Target$6.48$11.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
5/5/2026Reiterated Rating$4.66$11.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
5/5/2026Reiterated Rating$3.78$11.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/29/2026Boost Price Target$54.04$59.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
4/20/2026Reiterated Rating$4.20$11.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/16/2026Boost Price Target$46.31$58.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
4/16/2026Reiterated Rating$12.24$18.00Neutral
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
4/16/2026Reiterated Rating$4.83$11.00Outperform
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
4/16/2026Reiterated Rating$6.50$13.00Outperform
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad)

The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel

See the 5 stocks to avoid
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
4/13/2026Boost Price Target$64.47$80.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
4/13/2026Reiterated Rating$10.54$22.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4/8/2026Reiterated Rating$102.25$125.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
4/7/2026Reiterated Rating$9.09$22.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
4/2/2026Reiterated Rating$4.50$11.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
4/1/2026Boost Price Target$49.16$58.00Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
4/1/2026Lower Price Target$12.67$17.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3/31/2026Reiterated Rating$19.52$30.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
3/27/2026Reiterated Rating$4.41$11.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3/18/2026Reiterated Rating$4.95$11.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
3/17/2026Reiterated Rating$35.68$55.00Outperform
argenex SE stock logo
ARGX
argenex
3/9/2026Reiterated Rating$717.80$1,000.00Outperform
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
3/6/2026Boost Price Target$5.10$8.00Outperform
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3/5/2026Boost Price Target$1.08$5.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3/3/2026Boost Price Target$67.77$95.00Outperform
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2/25/2026Boost Price Target$32.29$65.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2/25/2026Boost Price Target$43.50$53.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2/24/2026Initiated Coverage$132.91$110.00Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
2/24/2026Reiterated Rating$11.71$20.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2/17/2026Lower Price Target$55.99$88.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
2/10/2026Reiterated Rating$5.69$11.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
1/30/2026Reiterated Rating$4.01$11.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
1/21/2026Reiterated Rating$39.90$55.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
1/15/2026Reiterated Rating$72.74Outperform
Immunome, Inc. stock logo
IMNM
Immunome
1/15/2026Reiterated Rating$20.76$31.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
1/15/2026Reiterated Rating$13.77$18.00Neutral
argenex SE stock logo
ARGX
argenex
1/14/2026Reiterated Rating$810.51$1,000.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
1/13/2026Reiterated Rating$17.43$30.00Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
1/13/2026Reiterated Rating$9.15$20.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
1/13/2026Boost Price Target$41.12$50.00Outperform
Generation Bio Co. stock logo
GBIO
Generation Bio
12/16/2025Set Price Target$5.39$5.50Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
12/8/2025Reiterated Rating$11.00$20.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
12/2/2025Reiterated Rating$40.07$48.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
11/17/2025Reiterated Rating$108.00$125.00Outperform
argenex SE stock logo
ARGX
argenex
11/14/2025Boost Price Target$894.31$1,000.00Outperform
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
11/10/2025Reiterated Rating$33.21$50.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
11/7/2025Lower Price Target$9.84$7.00Neutral
Xencor, Inc. stock logo
XNCR
Xencor
11/6/2025Reiterated Rating$14.24$26.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
10/30/2025Set Price Target$12.37$9.00
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
10/28/2025Reiterated Rating$40.45$48.00Outperform
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
10/27/2025Upgrade$1.65$7.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
10/17/2025Boost Price Target$74.36$110.00Outperform
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10/15/2025Boost Price Target$31.85$70.00Outperform
argenex SE stock logo
ARGX
argenex
10/13/2025Boost Price Target$796.92$880.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
10/13/2025Boost Price Target$37.89$44.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
10/13/2025Reiterated Rating$3.73$6.00Outperform
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
9/8/2025Initiated Coverage$1.55$4.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
9/8/2025Reiterated Rating$3.88$6.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
9/8/2025Reiterated Rating$80.89$115.00Outperform
Xencor, Inc. stock logo
XNCR
Xencor
9/2/2025Reiterated Rating$8.55$26.00Outperform
Buy this stock tomorrow (Ad)

Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership with Nvidia - one he believes positions it ahead of Tesla in the autonomous vehicle race. With a market-moving announcement expected on July 31st, Chaikin is urging investors to swap overpriced AI stocks for this under-the-radar name before markets open. He's also releasing a free Hotlist and Hitlist of buy and sell ideas for the second half of 2026.tc pixel

Get the ticker symbol and full details at no charge today
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
8/28/2025Reiterated Rating$12.10$22.00Outperform
Generation Bio Co. stock logo
GBIO
Generation Bio
8/13/2025Downgrade$4.05$7.00Neutral
Xencor, Inc. stock logo
XNCR
Xencor
8/7/2025Lower Price Target$7.49$26.00Outperform
ImageneBio, Inc. stock logo
IMA
ImageneBio
7/25/2025Lower Price Target$16.32$23.00Neutral
argenex SE stock logo
ARGX
argenex
6/24/2025Reiterated Rating$550.14$715.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
6/23/2025Reiterated Rating$3.53$11.00Outperform
argenex SE stock logo
ARGX
argenex
6/11/2025Reiterated Rating$575.46$715.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
6/11/2025Reiterated Rating$2.14$5.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
6/5/2025Initiated Coverage$17.48$22.00Outperform
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
5/28/2025Downgrade$10.43$12.00Neutral
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
5/19/2025Reiterated Rating$9.09$10.00Neutral
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
5/15/2025Reiterated Rating$2.24$5.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
4/16/2025Lower Price Target$15.66$27.00Neutral
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/16/2025Reiterated Rating$20.59$34.00Outperform
argenex SE stock logo
ARGX
argenex
4/11/2025Reiterated Rating$577.38$715.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
3/20/2025Reiterated Rating$8.64$33.00Outperform
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3/14/2025Downgrade$12.50$20.00Neutral
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
3/6/2025Reiterated Rating$0.91$5.00Neutral
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
2/6/2025Initiated Coverage$12.72$31.00Outperform
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2/3/2025Reiterated Rating$17.27$40.00Outperform

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Top Stock Recommendations by Brokerage